Registered number
13222505
Molecular Medical Ltd
Filleted Accounts
31 December 2023
Molecular Medical Ltd
Registered number: 13222505
Balance Sheet
as at 31 December 2023
Notes 2023 2022
£ £
Fixed assets
Tangible assets 3 62,605 56,192
Current assets
Debtors 4 142,486 392,151
Cash at bank and in hand 301,886 278,645
694,372 670,796
Creditors: amounts falling due within one year 5 (16,674) (723,035)
Net current assets/(liabilities) 677,698 (52,239)
Net assets 29,117 3,953
Capital and reserves
Called up share capital 100 100
Profit and loss account 29,017 3,853
Shareholders' funds 29,117 3,953
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
S Willis
Director
Approved by the board on 1 October 2024
Molecular Medical Ltd
Notes to the Accounts
for the year ended 31 December 2023
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Lab Equipment over 5 to 15 years
Office and computer equipment over 5 years
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
2 Employees 2023 2022
Number Number
Average number of persons employed by the company 3 3
3 Tangible fixed assets
Lab Equipment Plant and machinery etc Total
£ £ £
Cost
At 1 January 2023 53,375 2,817 56,192
Additions - 6,413 6,413
At 31 December 2023 53,375 9,230 62,605
Depreciation
At 31 December 2023 - - -
Net book value
At 31 December 2023 53,375 9,230 62,605
At 31 December 2022 53,375 2,817 56,192
4 Debtors 2023 2022
£ £
Trade debtors 130,048 370,740
Amounts owed by group undertakings and undertakings in which the company has a participating interest 9,004 19,799
Other debtors 3,434 1,612
142,486 392,151
5 Creditors: amounts falling due within one year 2023 2022
£ £
Trade creditors 23,761 7,568
Amounts owed to group undertakings and undertakings in which the company has a participating interest (9,064) 55,233
Taxation and social security costs - 689
Other creditors 1,977 659,545
16,674 723,035
6 Other information
Molecular Medical Ltd is a private company limited by shares and incorporated in England. Its registered office is:
2 Glenwood Villas
Fifield Lane
Frensham, Farnham
Surrey
GU10 3AR
Molecular Medical Ltd 13222505 false 2023-01-01 2023-12-31 2023-12-31 VT Final Accounts July 2024 S Willis No description of principal activity 13222505 2022-01-01 2022-12-31 13222505 core:WithinOneYear 2022-12-31 13222505 core:ShareCapital 2022-12-31 13222505 core:RetainedEarningsAccumulatedLosses 2022-12-31 13222505 2023-01-01 2023-12-31 13222505 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 13222505 bus:AuditExemptWithAccountantsReport 2023-01-01 2023-12-31 13222505 bus:Director40 2023-01-01 2023-12-31 13222505 1 2023-01-01 2023-12-31 13222505 2 2023-01-01 2023-12-31 13222505 core:LandBuildings 2023-01-01 2023-12-31 13222505 core:PlantMachinery 2023-01-01 2023-12-31 13222505 countries:England 2023-01-01 2023-12-31 13222505 bus:FRS102 2023-01-01 2023-12-31 13222505 bus:FilletedAccounts 2023-01-01 2023-12-31 13222505 2023-12-31 13222505 core:WithinOneYear 2023-12-31 13222505 core:ShareCapital 2023-12-31 13222505 core:RetainedEarningsAccumulatedLosses 2023-12-31 13222505 core:LandBuildings 2023-12-31 13222505 core:PlantMachinery 2023-12-31 13222505 2022-12-31 13222505 core:LandBuildings 2022-12-31 13222505 core:PlantMachinery 2022-12-31 iso4217:GBP xbrli:pure